Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial.

Lorenzen, S; Brucher, B; Zimmermann, F; Geinitz, H; Riera, J; Schuster, T; Roethling, N; Höfler, H; Ott, K; Peschel, C; Siewert, JR; Molls, M; Lordick, F

doi:10.1038/sj.bjc.6604659

journal article

Titel:: Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial.
Dokumenttyp:: Journal Article; Article
Autor(en):: Lorenzen, S; Brucher, B; Zimmermann, F; Geinitz, H; Riera, J; Schuster, T; Roethling, N; Höfler, H; Ott, K; Peschel, C; Siewert, JR; Molls, M; Lordick, F
Abstract:: Oxaliplatin and 5-fluorouracil have a significant activity in locally advanced oesophageal squamous cell cancer (OSCC). However, their optimal dosage and efficacy when combined with concurrent radiotherapy as neoadjuvant treatment are unknown. This non-randomised, phase I/II study aimed to define the maximum tolerated dose (MTD) and assessed the histopathological tumour response rate to neoadjuvant oxaliplatin in weekly escalating doses (40, 45, 50 mg m(-2)) and continuous infusional 5-fluorouracil (CI-5FU; 225 mg m(-2)) plus concurrent radiotherapy. Patients had resectable OSCC. Resection was scheduled for 4-6 weeks after chemoradiotherapy. During phase I (dose escalation; n=19), weekly oxaliplatin 45 mg m(-2) plus CI-5FU 225 mg m(-2) was established as the MTD and was the recommended dosage for phase II. Oesophageal mucositis was the dose-limiting toxicity at higher doses. During phase II, histopathological responses (<10% residual tumour cells within the specimen) were observed in 10 of 16 patients (63%; 95% confidence interval: 39-82%). Overall, 16 of the 25 patients (64%) who underwent resection had a histopathological response; tumour-free resection (R0) was achieved in 80%. Neoadjuvant weekly oxaliplatin 45 mg m(-2) plus CI-5FU 225 mg m(-2) with concurrent radiotherapy provides promising histological response rates and R0 resection rates in locally advanced OSCC.
Zeitschriftentitel:: Br J Cancer
Jahr:: 2008
Band / Volume:: 99
Heft / Issue:: 7
Seitenangaben Beitrag:: 1020-6
Sprache:: eng
Volltext / DOI:: doi:10.1038/sj.bjc.6604659
PubMed:: http://view.ncbi.nlm.nih.gov/pubmed/18797462
Print-ISSN:: 0007-0920
TUM Einrichtung:: III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie); Institut für Allgemeine Pathologie und Pathologische Anatomie; Institut für Medizinische Statistik und Epidemiologie; Klinik und Poliklinik für RadioOnkologie und Strahlentherapie
BibTeX

Vorkommen:

mediaTUM Gesamtbestand Einrichtungen Hochschulpräsidium TUM Senior Excellence Faculty EoE Publikationen 2008

mediaTUM Gesamtbestand Einrichtungen Schools TUM School of Medicine and Health Departments Clinical Medicine Institut für KI und Informatik in der Medizin (Prof. Rückert)2008

mediaTUM Gesamtbestand Einrichtungen Schools TUM School of Medicine and Health Departments Preclinical Medicine Institut für Allgemeine Pathologie und Pathologische Anatomie (Dr. Mogler komm.)2008

mediaTUM Gesamtbestand Einrichtungen Schools TUM School of Medicine and Health Departments Clinical Medicine Klinik und Poliklinik für RadioOnkologie und Strahlentherapie (Prof. Combs)2008

mediaTUM Gesamtbestand Hochschulbibliographie 2008 Fakultäten Medizin Institut für Medizinische Statistik und Epidemiologie

mediaTUM Gesamtbestand Einrichtungen Schools TUM School of Medicine and Health Departments Clinical Medicine Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie (Prof. Bassermann)2008

mediaTUM Gesamtbestand Hochschulbibliographie 2008 Fakultäten Medizin Institut für Allgemeine Pathologie und Pathologische Anatomie